Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth

Clinical Cancer Research

Volumn 11, Issue 3, 2005, Pages 1336-1341

  Ezzat, Shereen ^a   Huang, Ping ^a   Dackiw, Alan ^b   Asa, Sylvia L ^c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR; IMATINIB; PD 173074; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCID MOUSE; T LYMPHOCYTE; THYROID MEDULLARY CARCINOMA; TUMOR GROWTH; XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOMA, MEDULLARY; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; HUMANS; MICE; ONCOGENE PROTEINS; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RECEPTORS, FIBROBLAST GROWTH FACTOR; THYROID NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 12944284651     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Wells SA Jr, Franz C. Medullary carcinoma of the thyroid gland. World J Surg 2000;24:952-6.
2. Moley JF, Wells SA, Dilley WG, Tisell LE. Reoperation for recurrent or persistent medullary thyroid cancer. Surgery 1993; 114:1090-5.
3. Jing S, Wen D, Yu Y, et al. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-α, a novel receptor for GDNF. Cell 1996;85:1124.
4. Mulligan LM, Kwok JBJ, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-60.
5. Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994;6:70-4.
6. Eng C, Smith DP, Mulligan LM, et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 1994;3:237-41.
7. Mason IJ. The ins and outs of fibroblast growth factors. Cell 1994;78:547-52.
8. Eggo MC, Quiney VM, Campbell S. Local factors regulating growth and function of human thyroid cells in vitro and in vivo. Mol Cell Endocrinol 2003;213:47-58.
9. Boelaert K, McCabe CJ, Tannahill LA, et al. Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab 2003;88:2341-7.
10. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7.
11. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1:493-502.
12. Cohen P. Protein kinases - the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002;1:309-15.
13. Cohen MS, Hussain HB, Moley JF. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 2002;132:960-6.
14. Ezzat S, Zheng L, Yu S, Asa SL. A soluble dominant negative fibroblast growth factor receptor 4 isoform in human mcf-7 breast cancer cells. Biochem Biophys Res Commun 2001;287:60-5.
15. Yu S, Zheng L, Asa SL, Ezzat S. Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoter. Am J Physiol Endocrinol Metab 2002;283:E490-5.
16. Dackiw ABP, Ezzat S, Huang P, Liu W, Asa SL. Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in follicular thyroid carcinoma. Endocrinology (Baltimore) 2004;145:5840-6.
17. Hughes SE. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem 1997;45:1005-19.
18. Koziczak M, Holbro T, Hynes NE. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 2004;23:3501-8.
19. Mohammadi M, Froum S, Hamby JM, et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 1998;17:5896-904.
20. Dziba JM, Ain KB. Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro. J Clin Endocrinol Metab 2004;89:2127-35.
21. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
22. Partanen J, Mäkelä TP, Eerola E, et al. FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. EMBO J 1991;10:1347-54.
23. Revest JM, Spencer-Dene B, Kerr K, De Moerlooze L, Rosewell I, Dickson C. Fibroblast growth factor receptor 2-IIIb acts upstream of Shh and Fgf4 and is required for limb bud maintenance but not for the induction of Fgf8, Fgf10, Msx1, or Bmp4. Dev Biol 2001;231:47-62.
24. Onose H, Emoto N, Sugihara H, Shimizu K, Wakabayashi I. Overexpression of fibroblast growth factor receptor 3 in a human thyroid carcinoma cell line results in overgrowth of the confluent cultures. Eur J Endocrinol 1999;140:169-73.
25. Skaper SD, Kee WJ, Facci L, Macdonald G, Doherty P, Walsh FS. The FGFR1 inhibitor PD 173074 selectively and potently antagonizes FGF-2 neurotrophic and neurotropic effects. J Neurochem 2000;75: 1520-7.
26. Cavallaro U, Niedermeyer J, Fuxa M, Christofori G. N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat Cell Biol 2001;3:650-7.
27. Ezzat S, Zheng L, Asa SL. Tumor-derived FGFR4 isoform disrupts NCAM/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol Endocrinol 2004;18: 2543-52.
28. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002;21:6255-63.
29. Burris HA III. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004;9 Suppl 3:10-5.
30. Golubovskaya V, Beviglia L, Xu LH, Earp HS III, Craven R, Cance W. Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem 2002;277:38978-87.
31. Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 2002;109:69-78.